Search Results - "Lokku, Armend"

Summarizing the extent of visit irregularity in longitudinal data by Lokku, Armend, Lim, Lily S, Birken, Catherine S, Pullenayegum, Eleanor M

“…Observational longitudinal data often feature irregular, informative visit times. We propose descriptive measures to quantify the extent of irregularity to…”
Get full text

Latent classes of early response trajectories to biologics initiation in juvenile idiopathic arthritis: an analysis of four trials by Lim, Lily Siok Hoon, Shobhan, Shamsia, Lokku, Armend, Ringold, Sarah, Pullenayegum, Eleanor

“…Aims 1) To delineate latent classes of treatment response to biologics in juvenile idiopathic arthritis (JIA) patients in the first 16 weeks after initiation…”
Get full text

Cancer survivorship and opioid prescribing rates: A population‐based matched cohort study among individuals with and without a history of cancer by Sutradhar, Rinku, Lokku, Armend, Barbera, Lisa

“…BACKGROUND Little is known about opioid prescribing among individuals who have survived cancer. Our aim is to examine a predominantly socio‐economically…”
Get full text

Probability of Response in the First Sixteen Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials by Lim, Lily Siok Hoon, Lokku, Armend, Pullenayegum, Eleanor, Ringold, Sarah

“…Objectives Most juvenile idiopathic arthritis (JIA) biologic disease‐modifying antirheumatic drugs (bDMARDs) trials used an open‐label run‐in period followed…”
Get full text

Trends and Outcomes of Patent Ductus Arteriosus Treatment in Very Preterm Infants in Canada by Lokku, Armend, Mirea, Lucia, Lee, Shoo K, Shah, Prakeshkumar S

“…To assess trends in patent ductus arteriosus (PDA) management and examine concurrent changes in neonatal mortality and morbidities.  This retrospective…”
Get more information

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial by Isenberg, David, Furie, Richard, Jones, Nicholas S., Guibord, Pascal, Galanter, Joshua, Lee, Chin, McGregor, Anna, Toth, Balazs, Rae, Julie, Hwang, Olivia, Desai, Rupal, Lokku, Armend, Ramamoorthi, Nandhini, Hackney, Jason A., Miranda, Pedro, Souza, Viviane A., Jaller‐Raad, Juan J., Maura Fernandes, Anna, Garcia Salinas, Rodrigo, Chinn, Leslie W., Townsend, Michael J., Morimoto, Alyssa M., Tuckwell, Katie

“…Objective Fenebrutinib (GDC‐0853) is a noncovalent, oral, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK). The efficacy, safety, and…”
Get full text

CTNI-21. PIVOTAL, PHASE 2B RENEU TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMA (NF1-PN): A SPOTLIGHT ON PATIENTS ACHIEVING DEEP RESPONSE by Gershon, Timothy, Moertel, Christopher, McNall-Knapp, Rene, Shuhaiber, Hans, Weintraub, Lauren, Hajjar, Fouad, Nickerson, Molly, Weber, Michael, Lokku, Armend, Babovic-Vuksanovic, Dusica, Hirbe, Angela

Get full text

QOL-08. HEALTH-RELATED QUALITY-OF-LIFE (HRQOL) IN ADULTS AND CHILDREN WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMA (NF1-PN) TREATED WITH MIRDAMETINIB: PIVOTAL, PHASE 2B RENEU TRIAL by Babovic-Vuksanovic, Dusica, Hirbe, Angela, Moertel, Christopher, Shuhaiber, Hans, Sidhu, Alpa, Bielamowicz, Kevin, Viskochil, David, Bell, Timothy, Weber, Michael, Langseth, Abraham, Lokku, Armend, Weintraub, Lauren, Hajjar, Fouad, Foreman, Nick, Gershon, Timothy, McNall-Knapp, Rene

“…Patients with NF1-PN experience pain and other symptoms that negatively impact functioning and quality-of-life. We present patient- and parent proxy-reported…”
Get full text

CTNI-48. A PHASE 1 STUDY OF ERAS-801, A POTENT, SELECTIVE, AND CENTRAL NERVOUS SYSTEM (CNS)-PENETRANT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR, FOR PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM) by Wen, Patrick, Ahluwalia, Manmeet, Odia, Yazmin, McKean, Meredith, Snyder, James, Colman, Howard, Lobbous, Mina, Nghiemphu, Leia, Chong, Robert, Yang, Jennifer, Patel, Hina, Vecchio, Daniela, Lokku, Armend, Brail, Les, Mellinghoff, Ingo

“…EGFR is among the most common targets for genetic alterations in GBM. Changes in EGFR gene amplification and the extracellular domain result in receptor…”
Get full text

Summary Measures for Quantifying the Extent of Visit Irregularity in Longitudinal Data by Lokku, Armend

“…A common feature of observational longitudinal data is variability in the timings of visits across individuals. Irregular visits merit careful scrutiny as they…”
Get full text

Quantifying the extent of visit irregularity in longitudinal data by Lokku, Armend, Birken, Catherine S, Maguire, Jonathon L, Pullenayegum, Eleanor M

“…The timings of visits in observational longitudinal data may depend on the study outcome, and this can result in bias if ignored. Assessing the extent of visit…”
Get more information

Trends in unintentional injury mortality in Canadian children 1950–2009 and association with selected population-level interventions by Richmond, Sarah A., D’Cruz, Jennifer, Lokku, Armend, Macpherson, Alison, Howard, Andrew, Macarthur, Colin

“…OBJECTIVES : To examine unintentional injury mortality rates in children (0–19 years) in Canada from 1950 to 2009 against national population-level injury…”
Get full text

Trends in unintentional injury mortality in Canadian children 1950-2009 and with selected population-level interventions by Richmond, Sarah A, D'Cruz, Jennifer, Lokku, Armend, Macpherson, Alison, Howard, Andrew, Macarthur, Colin

“…OBJECTIVES: To examine unintentional injury mortality rates in children (0-19 years) in Canada from 1950 to 2009 against national population-level injury…”
Get full text